argenx SE
NASDAQ: ARGX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Timothy Van Hauwermeiren
- Employees
- 1,599
- Headquarters
- Amsterdam, Netherlands
- IPO year
- 2017
- Market cap
- $54.3B
- Website
- https://www.argenx.com
Loading ARGX…
Loading profile data…Frequently asked questions about ARGX
What does argenx SE (ARGX) do?
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is e...
Where does ARGX trade?
argenx SE (ARGX) trades on the NASDAQ Global Select.
What sector is ARGX in?
argenx SE (ARGX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of argenx SE?
Timothy Van Hauwermeiren is the chief executive officer of argenx SE (ARGX).
Where is argenx SE headquartered?
argenx SE is headquartered in Netherlands.
Does ARGX pay a dividend?
argenx SE (ARGX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARGX go public?
argenx SE (ARGX) completed its initial public offering in 2017.
Is ARGX an ADR?
Yes — ARGX is an American Depositary Receipt; its underlying shares trade on a non-US exchange. argenx SE reporting and dividends follow the underlying issuer.